C92.1
Chronic myeloid leukemia, BCR/ABL-positive
Clinical Classification Guidelines
Inclusion Terms
- Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive
- Chronic myelogenous leukemia, t(9;22) (q34;q11)
- Chronic myelogenous leukemia with crisis of blast cells
Excludes Type 1
- atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
- chronic myelomonocytic leukemia (C93.1-)
- chronic myeloproliferative disease (D47.1)
Medical Intelligence & Overview
Chronic myeloid leukemia (CML), classified under ICD-10 code C92.1, is a type of blood cancer that originates in the bone marrow, where blood cells are produced. This form of leukemia is characterized by the uncontrolled growth of myeloid cells, a type of white blood cell. It is distinct because it is typically associated with a specific genetic abnormality called the Philadelphia chromosome, which leads to the BCR/ABL fusion gene. This mutation results in abnormal cell growth and division, ultimately causing CML. It often develops slowly over time and may initially produce few symptoms, making early detection challenging.
Causes & Symptoms
Clinical Causes: The primary cause of CML is the presence of the Philadelphia chromosome, a genetic abnormality where parts of chromosomes 9 and 22 swap places (translocation t(9;22)(q34;q11)). This translocation creates the BCR/ABL fusion gene, which encodes an abnormal enzyme that promotes uncontrolled leukemia cell growth. The exact reason why the Philadelphia chromosome forms is not well understood, but genetic mutations and environmental factors may play a role. There are no clear lifestyle or environmental exposures that directly cause CML, making it largely a genetic mutation-driven disease.
Key Symptoms: Fatigue and weakness Unexplained weight loss Night sweats Fever Enlarged spleen or liver, which may cause abdominal discomfort or fullness Easy bruising or bleeding Frequent infections Bone pain or tenderness Feeling full after eating small amounts of food
Diagnostic & Treatment
Diagnosis Path: Complete blood count (CBC) to identify abnormal white blood cell levels Bone marrow biopsy to examine marrow cells directly Cytogenetic analysis to detect the Philadelphia chromosome Molecular testing for BCR/ABL fusion gene presence Imaging tests like ultrasound or CT scans if organ involvement or enlarged spleen is suspected
Treatment Protocols: Targeted therapy with tyrosine kinase inhibitors (TKIs) such as imatinib, which specifically inhibit the BCR/ABL enzyme Interferon therapy in some cases, to boost the immune response Chemotherapy, often used in advanced phases or blast crisis Stem cell or bone marrow transplantation, which may be considered for certain patients Regular monitoring through blood tests and molecular assessments to track treatment response and disease progression
Clinical Advice & FAQs
Billing Guidance
Is C92.1 a billable ICD-10 code?
Yes, C92.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.1?
Clinical documentation must specify the nature of Chronic myeloid leukemia, BCR/ABL-positive and any associated comorbidities for accurate reporting.
Cite this Clinical Reference